Amadeo Sáez-Alquézar
Amadeo Sáez-Alquézar has a total of 191 co-authors. Here are the top co-authors by number of shared publications:
S Raia
10 shared publicationsL C Da Silva
8 shared publicationsA Raia
5 shared publicationsN Ohtsuki
5 shared publicationsS Mies
5 shared publicationsDalton F. Chamone
Fundação Pró-Sangue, São Paulo, Brasil
4 shared publications
Latest Publications
- Open Access
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Memórias do Instituto Oswaldo Cruz
- Vol. 116
Geographical origin of chronic Chagas disease patients in Brazil impacts the performance of commercial tests for anti-T. cruzi IgG
Chagas disease, caused by Trypanosoma cruzi, affects nearly six million people worldwide. Various serological tests have been developed for its diagnosis. Examine the performance of a set of commercial immunological assays in relation to the geographical origin of the patient sample comparing four states of Brazil: Amazonas (AM), Mato Grosso do Sul (MS), Minas Gerais (MG) and Piauí (PI). Seven immunoassays were employed to detect anti-T. cruzi IgG antibodies in 379 patient samples that had been previously diagnosed using the two-step protocol required by the Brazilian Ministry of Health. A significant variation in the percent reactive was calculated for the samples from AM and MS, while the PI and MG showed a significant variation in the percent non-reactive. The average reactivity index was significantly higher for samples from the states of PI and MG states than AM and MS. All tests presented a satisfactory performance overall. Yet, variations were observed that were associated to the region of origin of the samples. Our analyses suggest that future evaluations of immunoassays should include a sampling of sera from regions where the test will be applied in addition to the available International Biological Reference Standards.
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Memórias do Instituto Oswaldo Cruz
- Vol. 116
Open AccessGeographical origin of chronic Chagas disease patients in Brazil impacts the performance of commercial tests for anti-T. cruzi IgG
Chagas disease, caused by Trypanosoma cruzi, affects nearly six million people worldwide. Various serological tests have been developed for its diagnosis. Examine the performance of a set of commercial immunological assays in relation to the geographical origin of the patient sample comparing four states of Brazil: Amazonas (AM), Mato Grosso do Sul (MS), Minas Gerais (MG) and Piauí (PI). Seven immunoassays were employed to detect anti-T. cruzi IgG antibodies in 379 patient samples that had been previously diagnosed using the two-step protocol required by the Brazilian Ministry of Health. A significant variation in the percent reactive was calculated for the samples from AM and MS, while the PI and MG showed a significant variation in the percent non-reactive. The average reactivity index was significantly higher for samples from the states of PI and MG states than AM and MS. All tests presented a satisfactory performance overall. Yet, variations were observed that were associated to the region of origin of the samples. Our analyses suggest that future evaluations of immunoassays should include a sampling of sera from regions where the test will be applied in addition to the available International Biological Reference Standards.
- Open Access
- 1 January 2020
- Published by FapUNIFESP (SciELO) in Memórias do Instituto Oswaldo Cruz
- Vol. 115, e200214
Application of WHO International Biological Reference Standards to evaluate commercial serological tests for chronic Chagas disease
It is of fundamental importance to accurately diagnosis T. cruzi infections through laboratory tests for the administration of the best course of patient treatment to curb disease progression and the prevention of disease transmission. Parasitological tests for T. cruzi infections can directly observe parasites in blood smears3,8,9,10 or after concentration techniques such as centrifugation, Strout method and microhematocrit. The detection of portions of the T. cruzi genome circulating in blood is also possible through molecular biology techniques.3,11 Blood smears are primarily reserved for diagnosing the acute phase or reactivation of an infection due to immunodepression, which corresponds to a high parasitaemia in the blood of infected individuals.3,8,9,10 In the transition to the chronic phase, the number of circulating parasites usually fall below the level of feasible detection through parasitological tests. While polymerase chain reaction (PCR) amplification can show greater sensitivity than parasitological tests, it still requires the capture of parasite nucleic acid in the patient sample for an accurate diagnosis.9,11,12,13,14 Its use as a diagnostic tool is further limited by the high costs of reagents and specialised equipment that require trained personnel and infrastructure as well as the absence of standardisation on a global scale.15,16
- 1 January 2020
- Published by FapUNIFESP (SciELO) in Memórias do Instituto Oswaldo Cruz
- Vol. 115, e200214
Open AccessApplication of WHO International Biological Reference Standards to evaluate commercial serological tests for chronic Chagas disease
It is of fundamental importance to accurately diagnosis T. cruzi infections through laboratory tests for the administration of the best course of patient treatment to curb disease progression and the prevention of disease transmission. Parasitological tests for T. cruzi infections can directly observe parasites in blood smears3,8,9,10 or after concentration techniques such as centrifugation, Strout method and microhematocrit. The detection of portions of the T. cruzi genome circulating in blood is also possible through molecular biology techniques.3,11 Blood smears are primarily reserved for diagnosing the acute phase or reactivation of an infection due to immunodepression, which corresponds to a high parasitaemia in the blood of infected individuals.3,8,9,10 In the transition to the chronic phase, the number of circulating parasites usually fall below the level of feasible detection through parasitological tests. While polymerase chain reaction (PCR) amplification can show greater sensitivity than parasitological tests, it still requires the capture of parasite nucleic acid in the patient sample for an accurate diagnosis.9,11,12,13,14 Its use as a diagnostic tool is further limited by the high costs of reagents and specialised equipment that require trained personnel and infrastructure as well as the absence of standardisation on a global scale.15,16
- Open Access
- 27 November 2015
- Vol. 26 (4) , 278-285
Quality Control in Screening for Infectious Diseases at Blood Banks. Rationale and Methodology
Quality control procedures are indispensable to ensure the reliability of the results provided by laboratories responsible for serological screening in blood banks. International recommendations on systems of quality management classify as a top component the inclusion of two types of control: (a) internal quality control (IQC) and (b) external quality control (EQC). In EQC it is essential to have, at least, a monthly frequency of laboratory assessment. On the other hand, IQC involves the daily use of low-reactivity control sera, which should be systematically added in all run, carried out in the laboratory for each parameter. Through the IQC analysis some variations in the criteria of run acceptance and rejection may be revealed, but it is of paramount importance to ensure the previous definition of these criteria and even more importantly, the adherence to them; and that corresponds to the validation of analytical runs of each test. Since 2010 this has been, for instance, the experience of the PNCQ*, developing external quality control programmes on serology for blood banks. These programmes use samples of lyophilized sera well-characterized for the reactivity related to the parameters used for the serological screening of blood donors. The programmes have used blind panels of six samples for monthly assessments. In the last 50 assessments, which involved 68 blood banks in Brazil, a significant number of instances of non-compliance were observed in all monthly assessments. These results provide strong support to the recommendation of systematic monthly assessments.
- 27 November 2015
- Vol. 26 (4) , 278-285
Open AccessQuality Control in Screening for Infectious Diseases at Blood Banks. Rationale and Methodology
Quality control procedures are indispensable to ensure the reliability of the results provided by laboratories responsible for serological screening in blood banks. International recommendations on systems of quality management classify as a top component the inclusion of two types of control: (a) internal quality control (IQC) and (b) external quality control (EQC). In EQC it is essential to have, at least, a monthly frequency of laboratory assessment. On the other hand, IQC involves the daily use of low-reactivity control sera, which should be systematically added in all run, carried out in the laboratory for each parameter. Through the IQC analysis some variations in the criteria of run acceptance and rejection may be revealed, but it is of paramount importance to ensure the previous definition of these criteria and even more importantly, the adherence to them; and that corresponds to the validation of analytical runs of each test. Since 2010 this has been, for instance, the experience of the PNCQ*, developing external quality control programmes on serology for blood banks. These programmes use samples of lyophilized sera well-characterized for the reactivity related to the parameters used for the serological screening of blood donors. The programmes have used blind panels of six samples for monthly assessments. In the last 50 assessments, which involved 68 blood banks in Brazil, a significant number of instances of non-compliance were observed in all monthly assessments. These results provide strong support to the recommendation of systematic monthly assessments.
- Open Access
- 1 July 2014
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 52 (7) , 2506-2512
Comparative Evaluation of 11 Commercialized Rapid Diagnostic Tests for Detecting Trypanosoma cruzi Antibodies in Serum Banks in Areas of Endemicity and Nonendemicity
Chagas disease is one of the main public health issues in Latin America. Increasingly during the past few decades, Trypanosoma cruzi infection has been detected in North America, Europe, and the Western Pacific, mainly as a result of population movement. The limited availability of rapid serological diagnostic tests hinders rapid diagnosis and early treatment in areas of endemicity and nonendemicity. In collaboration with 11 national reference laboratories (NRLs) from different geographical areas, we evaluated the performances of commercialized serological rapid diagnostic tests (RDT) for T. cruzi infection. Eleven commercialized T. cruzi infection RDTs were evaluated on a total of 474 samples extensively tested with at least three different techniques for Chagas disease, maintained at controlled low temperatures, and stored in the serum banks of the 11 NRLs. We measured the sensitivity, specificity, and concordance of each RDT and provided an additional questionnaire to evaluate its ease of use. The selected RDTs in this study were performed under controlled laboratory conditions. Out of the 11 RDTs, we found 8 of them to be useful, with the cassette format favored over the strip. We did not observe significant differences in RDT performances in the different regions. Overall, the performance results were lower than those disclosed by the manufacturers. The results of this evaluation validate the possibility of using RDTs to diagnose Chagas disease, thereby decreasing the time to treatment at a primary health care facility for patients who are willing to be treated. Further studies should be conducted in the laboratory and in the field to confirm these data, expressly to evaluate reproducibility in resource-limited settings, or using whole blood in clinical settings in areas of endemicity and nonendemicity.
- 1 July 2014
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 52 (7) , 2506-2512
Open AccessComparative Evaluation of 11 Commercialized Rapid Diagnostic Tests for Detecting Trypanosoma cruzi Antibodies in Serum Banks in Areas of Endemicity and Nonendemicity
Chagas disease is one of the main public health issues in Latin America. Increasingly during the past few decades, Trypanosoma cruzi infection has been detected in North America, Europe, and the Western Pacific, mainly as a result of population movement. The limited availability of rapid serological diagnostic tests hinders rapid diagnosis and early treatment in areas of endemicity and nonendemicity. In collaboration with 11 national reference laboratories (NRLs) from different geographical areas, we evaluated the performances of commercialized serological rapid diagnostic tests (RDT) for T. cruzi infection. Eleven commercialized T. cruzi infection RDTs were evaluated on a total of 474 samples extensively tested with at least three different techniques for Chagas disease, maintained at controlled low temperatures, and stored in the serum banks of the 11 NRLs. We measured the sensitivity, specificity, and concordance of each RDT and provided an additional questionnaire to evaluate its ease of use. The selected RDTs in this study were performed under controlled laboratory conditions. Out of the 11 RDTs, we found 8 of them to be useful, with the cassette format favored over the strip. We did not observe significant differences in RDT performances in the different regions. Overall, the performance results were lower than those disclosed by the manufacturers. The results of this evaluation validate the possibility of using RDTs to diagnose Chagas disease, thereby decreasing the time to treatment at a primary health care facility for patients who are willing to be treated. Further studies should be conducted in the laboratory and in the field to confirm these data, expressly to evaluate reproducibility in resource-limited settings, or using whole blood in clinical settings in areas of endemicity and nonendemicity.
- Open Access
- 14 January 2008
- Published by Universidade Federal de Goias in Revista de Patologia Tropical / Journal of Tropical Pathology
- Vol. 36 (3) , 215-228
DESEMPENHO DE TESTES SOROLÓGICOS PARA SÍFILIS, TREPONÊMICOS (ELISA) E NÃO TREPONÊMICOS (VDRL E RPR), NA TRIAGEM SOROLÓGICA PARA DOADORES DE SANGUE – CONFIRMAÇÃO DOS RESULTADOS POR MEIO DE TRÊS TESTES TREPONÊMICOS (FTA ABS, WB E TPHA)
Este estudo constitui uma análise do desempenho do teste sorológico treponêmico ELISA Recombinante Wiener lab. e de seis testes não treponêmicos (Laborclin: VDRL Bras, RPR Brás e RPR TRUST; Wama: VDRL e RPR; Wiener: USR) na triagem sorológica de doadores de sangue. Os resultados repetidamente reagentes (RR) foram confirmados por meio de três testes treponêmicos: FTA abs (Wama), WB (in house) e TPHA (bioMérieux). Foram analisadas 2.990 amostras de soro. O teste VDRL (USR), utilizado inicialmente na triagem sorológica, apresentou reatividade em 11 (0,4 %) amostras, com títulos variando de 1/1 até 1/32. Nos demais testes não treponêmicos, observou-se reatividade em um número de amostras que variou de 4 a 14, num total de 20 (0,7 %) amostras das 2.990 analisadas. O teste treponêmico ELISA apresentou resultados RR em 42 (1,4 %) das amostras analisadas, entre as quais 8 (0,3 %) se mostraram reagentes a, pelo menos, um teste não treponêmico. Das 42 amostras RR pelo teste ELISA submetidas aos testes confirmatórios de FTA-abs, TPHA e WB, 9 (21,4 %) foram negativas para os três testes, 8 (19,1 %) foram positivas para WB e TPHA e negativas para o FTA-abs e 25 (59,5 %) foram positivas para os três testes. A especificidade do teste ELISA atingiu 99,7%, considerando-se o WB e o TPHA como confirmatórios. As 12 amostras que apresentaram resultados não reagentes no teste ELISA, mas mostraram algum tipo de reatividade para os testes não treponêmicos, tiveram resultado negativo nos testes confirmatórios utilizados. Mesmo que o descarte de bolsas seja maior quando se utiliza teste treponêmico, essa conduta parece ser a mais segura na triagem sorológica de doadores de sangue.
- 14 January 2008
- Published by Universidade Federal de Goias in Revista de Patologia Tropical / Journal of Tropical Pathology
- Vol. 36 (3) , 215-228
Open AccessDESEMPENHO DE TESTES SOROLÓGICOS PARA SÍFILIS, TREPONÊMICOS (ELISA) E NÃO TREPONÊMICOS (VDRL E RPR), NA TRIAGEM SOROLÓGICA PARA DOADORES DE SANGUE – CONFIRMAÇÃO DOS RESULTADOS POR MEIO DE TRÊS TESTES TREPONÊMICOS (FTA ABS, WB E TPHA)
Este estudo constitui uma análise do desempenho do teste sorológico treponêmico ELISA Recombinante Wiener lab. e de seis testes não treponêmicos (Laborclin: VDRL Bras, RPR Brás e RPR TRUST; Wama: VDRL e RPR; Wiener: USR) na triagem sorológica de doadores de sangue. Os resultados repetidamente reagentes (RR) foram confirmados por meio de três testes treponêmicos: FTA abs (Wama), WB (in house) e TPHA (bioMérieux). Foram analisadas 2.990 amostras de soro. O teste VDRL (USR), utilizado inicialmente na triagem sorológica, apresentou reatividade em 11 (0,4 %) amostras, com títulos variando de 1/1 até 1/32. Nos demais testes não treponêmicos, observou-se reatividade em um número de amostras que variou de 4 a 14, num total de 20 (0,7 %) amostras das 2.990 analisadas. O teste treponêmico ELISA apresentou resultados RR em 42 (1,4 %) das amostras analisadas, entre as quais 8 (0,3 %) se mostraram reagentes a, pelo menos, um teste não treponêmico. Das 42 amostras RR pelo teste ELISA submetidas aos testes confirmatórios de FTA-abs, TPHA e WB, 9 (21,4 %) foram negativas para os três testes, 8 (19,1 %) foram positivas para WB e TPHA e negativas para o FTA-abs e 25 (59,5 %) foram positivas para os três testes. A especificidade do teste ELISA atingiu 99,7%, considerando-se o WB e o TPHA como confirmatórios. As 12 amostras que apresentaram resultados não reagentes no teste ELISA, mas mostraram algum tipo de reatividade para os testes não treponêmicos, tiveram resultado negativo nos testes confirmatórios utilizados. Mesmo que o descarte de bolsas seja maior quando se utiliza teste treponêmico, essa conduta parece ser a mais segura na triagem sorológica de doadores de sangue.
- 1 August 2007
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 14 (8) , 1045-1049
Evaluation of Serological Tests To Identify Trypanosoma cruzi Infection in Humans and Determine Cross-Reactivity with Trypanosoma rangeli and Leishmania spp
Five commercially available enzyme-linked immunosorbent assays (ELISAs), one in-house ELISA, and two hemagglutination assays were evaluated to determine their diagnostic accuracy for Chagas' disease in two studies. In study 1, ELISA kits showed 100% sensitivity, but specificities ranged from 82.84% to 100% when leishmaniasis cases were included and from 95.57% to 100% when leishmaniasis cases were excluded. Kits using recombinant antigens or synthetic peptides are more specific than those using crude extracts from Trypanosoma cruzi epimastigote forms. Kits evaluated in Panama, in study 2, showed 75% to 100% sensitivity and 97.12% to 100% specificity. These data were obtained by using a Western blot assay with T. cruzi trypomastigote excreted-secreted antigens as a reference test to confirm T. cruzi infection.
- 1 August 2007
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 14 (8) , 1045-1049
Evaluation of Serological Tests To Identify Trypanosoma cruzi Infection in Humans and Determine Cross-Reactivity with Trypanosoma rangeli and Leishmania spp
Five commercially available enzyme-linked immunosorbent assays (ELISAs), one in-house ELISA, and two hemagglutination assays were evaluated to determine their diagnostic accuracy for Chagas' disease in two studies. In study 1, ELISA kits showed 100% sensitivity, but specificities ranged from 82.84% to 100% when leishmaniasis cases were included and from 95.57% to 100% when leishmaniasis cases were excluded. Kits using recombinant antigens or synthetic peptides are more specific than those using crude extracts from Trypanosoma cruzi epimastigote forms. Kits evaluated in Panama, in study 2, showed 75% to 100% sensitivity and 97.12% to 100% specificity. These data were obtained by using a Western blot assay with T. cruzi trypomastigote excreted-secreted antigens as a reference test to confirm T. cruzi infection.
- 1 March 2003
- Published by FapUNIFESP (SciELO) in Revista Panamericana de Salud Pública
- Vol. 13 (2-3) , 129-137
Resultados de un programa de control de calidad externo del tamizaje serológico de anticuerpos contra Trypanosoma cruzi en donantes de sangre de Brasil
- 1 March 2003
- Published by FapUNIFESP (SciELO) in Revista Panamericana de Salud Pública
- Vol. 13 (2-3) , 129-137
Resultados de un programa de control de calidad externo del tamizaje serológico de anticuerpos contra Trypanosoma cruzi en donantes de sangre de Brasil
- 1 March 2003
- Published by FapUNIFESP (SciELO) in Revista Panamericana de Salud Pública
- Vol. 13 (2-3) , 91-102
Programas de control externo de la calidad en serología desarrollados en América Latina con el apoyo de la OPS entre 1997 y 2000
To evaluate the quality of serological screening of blood donors in five groups of blood banks in Latin America that participated over the 1997-2000 period in an external serology control project developed with support from the Pan American Health Organization (PAHO). With assistance from PAHO, the Serology Authority of the Pro-Blood Foundation/Blood Center of São Paulo (Fundação Pró-Sangue/Hemocentro de São Paulo), of São Paulo, Brazil, carried out the external quality control project and served as its "organizing center" (OC). The OC developed five external serology quality control "programs" (ESQCPs), or external evaluation activities, for the respective groups of participating blood banks. There was one ESQCP each in 1997, 1999, and 2000, and there were two in 1998. In these five programs, the number of participating blood banks ranged from 13 to 21, and the number of countries ranged from 11 to 16. In each program, the OC used a set of 24 blinded sera samples with different reactivities for the various infectious agents for which screening is obligatory in Brazil. Each participating institution in each program received a sera set, to be processed using that institution's standard screening procedures. After returning its results to the OC, each participant received an answer key for the sera set, to be used in evaluating its own performance. All the individual results were kept strictly confidential. At the end of each program, the OC prepared and sent to all the participants a final report that contained information on the overall results from that program. An analysis of the five programs showed that there was a lack of homogeneity among the countries with respect to the strategies and the parameters used in screening blood donors. Few laboratories screened for human T-cell-lymphotropic virus (beginning with the 1997 program, the respective rates were 17%, 27%, 35%, 39%, and 45%). Rates of screening were also low for antibodies to the hepatitis B core antigen (again, beginning with the 1997 program, the rates were 42%, 27%, 39%, 50%, and 60%). There were also important differences with respect to which tests and which combinations of tests were used, making it hard to compare the types of screening done. In the five programs, with the various tests used, the overall rate of false positive results fluctuated around 2%. The highest false positive rate for any of the tests, 4.6%, was for antibodies against the hepatitis C virus. The lowest false positive rate, 0.4%, was for antibodies against Trypanosoma cruzi. These results show the need for PAHO to continue using these external quality control programs as well as other activities in order to strengthen the procedures for serological screening blood banks in Latin America, until there is more uniformity in the procedures that the countries use.
- 1 March 2003
- Published by FapUNIFESP (SciELO) in Revista Panamericana de Salud Pública
- Vol. 13 (2-3) , 91-102
Programas de control externo de la calidad en serología desarrollados en América Latina con el apoyo de la OPS entre 1997 y 2000
To evaluate the quality of serological screening of blood donors in five groups of blood banks in Latin America that participated over the 1997-2000 period in an external serology control project developed with support from the Pan American Health Organization (PAHO). With assistance from PAHO, the Serology Authority of the Pro-Blood Foundation/Blood Center of São Paulo (Fundação Pró-Sangue/Hemocentro de São Paulo), of São Paulo, Brazil, carried out the external quality control project and served as its "organizing center" (OC). The OC developed five external serology quality control "programs" (ESQCPs), or external evaluation activities, for the respective groups of participating blood banks. There was one ESQCP each in 1997, 1999, and 2000, and there were two in 1998. In these five programs, the number of participating blood banks ranged from 13 to 21, and the number of countries ranged from 11 to 16. In each program, the OC used a set of 24 blinded sera samples with different reactivities for the various infectious agents for which screening is obligatory in Brazil. Each participating institution in each program received a sera set, to be processed using that institution's standard screening procedures. After returning its results to the OC, each participant received an answer key for the sera set, to be used in evaluating its own performance. All the individual results were kept strictly confidential. At the end of each program, the OC prepared and sent to all the participants a final report that contained information on the overall results from that program. An analysis of the five programs showed that there was a lack of homogeneity among the countries with respect to the strategies and the parameters used in screening blood donors. Few laboratories screened for human T-cell-lymphotropic virus (beginning with the 1997 program, the respective rates were 17%, 27%, 35%, 39%, and 45%). Rates of screening were also low for antibodies to the hepatitis B core antigen (again, beginning with the 1997 program, the rates were 42%, 27%, 39%, 50%, and 60%). There were also important differences with respect to which tests and which combinations of tests were used, making it hard to compare the types of screening done. In the five programs, with the various tests used, the overall rate of false positive results fluctuated around 2%. The highest false positive rate for any of the tests, 4.6%, was for antibodies against the hepatitis C virus. The lowest false positive rate, 0.4%, was for antibodies against Trypanosoma cruzi. These results show the need for PAHO to continue using these external quality control programs as well as other activities in order to strengthen the procedures for serological screening blood banks in Latin America, until there is more uniformity in the procedures that the countries use.
- 1 October 1999
- Published by Wiley in Transfusion
- Vol. 39 (10) , 1152
Estimated risk of transfusion-transmitted HIV infection in Sao Paulo, Brazil
- 1 October 1999
- Published by Wiley in Transfusion
- Vol. 39 (10) , 1152
Estimated risk of transfusion-transmitted HIV infection in Sao Paulo, Brazil
- 1 July 1999
- Published by FapUNIFESP (SciELO) in Revista Panamericana de Salud Pública
- Vol. 6 (1) , 69-73
Anti-HBc testing for blood donations in areas with intermediate hepatitis B endemicity
- 1 July 1999
- Published by FapUNIFESP (SciELO) in Revista Panamericana de Salud Pública
- Vol. 6 (1) , 69-73
Anti-HBc testing for blood donations in areas with intermediate hepatitis B endemicity